127 related articles for article (PubMed ID: 38287694)
1. Influence of
Thomas L; Raju AP; Chaithra S; Kulavalli S; Varma M; Sv CS; Baneerjee M; Saravu K; Mallayasamy S; Rao M
Expert Rev Clin Pharmacol; 2024 Mar; 17(3):263-274. PubMed ID: 38287694
[TBL] [Abstract][Full Text] [Related]
2. NAT2 slow acetylator associated with anti-tuberculosis drug-induced liver injury in Thai patients.
Wattanapokayakit S; Mushiroda T; Yanai H; Wichukchinda N; Chuchottawon C; Nedsuwan S; Rojanawiwat A; Denjanta S; Kantima T; Wongyai J; Suwankesawong W; Rungapiromnan W; Kidkeukarun R; Bamrungram W; Chaiwong A; Suvichapanich S; Mahasirimongkol S; Tokunaga K
Int J Tuberc Lung Dis; 2016 Oct; 20(10):1364-1369. PubMed ID: 27725049
[TBL] [Abstract][Full Text] [Related]
3. Polymorphism of the N-acetyltransferase 2 gene as a susceptibility risk factor for antituberculosis drug-induced hepatotoxicity in Tunisian patients with tuberculosis.
Ben Mahmoud L; Ghozzi H; Kamoun A; Hakim A; Hachicha H; Hammami S; Sahnoun Z; Zalila N; Makni H; Zeghal K
Pathol Biol (Paris); 2012 Oct; 60(5):324-30. PubMed ID: 21856096
[TBL] [Abstract][Full Text] [Related]
4. Polymorphisms of NAT2, CYP2E1, GST, and HLA related to drug-induced liver injury in indonesian tuberculosis patients.
Perwitasari DA; Darmawan E; Mulyani UA; Vlies PV; Alffenaar JC; Atthobar J; Wilffert B
Int J Mycobacteriol; 2018; 7(4):380-386. PubMed ID: 30531039
[TBL] [Abstract][Full Text] [Related]
5. NAT2 genotype guided regimen reduces isoniazid-induced liver injury and early treatment failure in the 6-month four-drug standard treatment of tuberculosis: a randomized controlled trial for pharmacogenetics-based therapy.
Azuma J; Ohno M; Kubota R; Yokota S; Nagai T; Tsuyuguchi K; Okuda Y; Takashima T; Kamimura S; Fujio Y; Kawase I;
Eur J Clin Pharmacol; 2013 May; 69(5):1091-101. PubMed ID: 23150149
[TBL] [Abstract][Full Text] [Related]
6. Association and clinical utility of NAT2 in the prediction of isoniazid-induced liver injury in Singaporean patients.
Chan SL; Chua APG; Aminkeng F; Chee CBE; Jin S; Loh M; Gan SH; Wang YT; Brunham LR
PLoS One; 2017; 12(10):e0186200. PubMed ID: 29036176
[TBL] [Abstract][Full Text] [Related]
7. NAT2 variants are associated with drug-induced liver injury caused by anti-tuberculosis drugs in Indonesian patients with tuberculosis.
Yuliwulandari R; Susilowati RW; Wicaksono BD; Viyati K; Prayuni K; Razari I; Kristin E; Syafrizal ; Subagyo ; Sri Diana E; Setiawati S; Ariyani A; Mahasirimongkol S; Yanai H; Mushiroda T; Tokunaga K
J Hum Genet; 2016 Jun; 61(6):533-7. PubMed ID: 26911349
[TBL] [Abstract][Full Text] [Related]
8. Homozygotes NAT2*5B slow acetylators are highly associated with hepatotoxicity induced by anti-tuberculosis drugs.
El-Jaick KB; Ribeiro-Alves M; Soares MVG; Araujo GEF; Pereira GRC; Rolla VC; Mesquita JF; De Castro L
Mem Inst Oswaldo Cruz; 2022; 117():e210328. PubMed ID: 35588539
[TBL] [Abstract][Full Text] [Related]
9. NAT2 and CYP2E1 polymorphisms and antituberculosis drug-induced hepatotoxicity in Peruvian patients.
Jaramillo-Valverde L; Levano KS; Tarazona DD; Capristano S; Zegarra-Chapoñan R; Sanchez C; Yufra-Picardo VM; Tarazona-Santos E; Ugarte-Gil C; Guio H
Mol Genet Genomic Med; 2022 Aug; 10(8):e1987. PubMed ID: 35751408
[TBL] [Abstract][Full Text] [Related]
10. NAT2 polymorphisms and susceptibility to anti-tuberculosis drug-induced liver injury: a meta-analysis.
Wang PY; Xie SY; Hao Q; Zhang C; Jiang BF
Int J Tuberc Lung Dis; 2012 May; 16(5):589-95. PubMed ID: 22409928
[TBL] [Abstract][Full Text] [Related]
11. The association between the NAT2 genetic polymorphisms and risk of DILI during anti-TB treatment: a systematic review and meta-analysis.
Zhang M; Wang S; Wilffert B; Tong R; van Soolingen D; van den Hof S; Alffenaar JW
Br J Clin Pharmacol; 2018 Dec; 84(12):2747-2760. PubMed ID: 30047605
[TBL] [Abstract][Full Text] [Related]
12. Efficacy, safety, and pharmacokinetics of isoniazid affected by NAT2 polymorphisms in patients with tuberculosis: A systematic review.
Surarak T; Chumnumwat S; Nosoongnoen W; Tragulpiankit P
Clin Transl Sci; 2024 Apr; 17(4):e13795. PubMed ID: 38629592
[TBL] [Abstract][Full Text] [Related]
13. N-acetyltransferase 2 (NAT2) genotype as a risk factor for development of drug-induced liver injury relating to antituberculosis drug treatment in a mixed-ethnicity patient group.
Ng CS; Hasnat A; Al Maruf A; Ahmed MU; Pirmohamed M; Day CP; Aithal GP; Daly AK
Eur J Clin Pharmacol; 2014 Sep; 70(9):1079-86. PubMed ID: 24888881
[TBL] [Abstract][Full Text] [Related]
14. [The associations of polymorphism of N-acetyltransferase 2 gene is associated with antituberculosis drug-induced hepatotoxicity in tuberculosis patients].
An HR; Wu XQ; Wang ZY; Liang Y; Zhang JX
Zhonghua Yu Fang Yi Xue Za Zhi; 2011 Jan; 45(1):36-40. PubMed ID: 21418817
[TBL] [Abstract][Full Text] [Related]
15. NAT2 Genotypes in Moroccan Patients with Hepatotoxicity Due to Antituberculosis Drugs.
Guaoua S; Ratbi I; El Bouazzi O; Hammi S; Tebaa A; Bourkadi JE; Bencheikh RS; Sefiani A
Genet Test Mol Biomarkers; 2016 Nov; 20(11):680-684. PubMed ID: 27541622
[TBL] [Abstract][Full Text] [Related]
16. Hepatotoxicity during TB treatment in people with HIV/AIDS related to NAT2 polymorphisms in Pernambuco, Northeast Brazil.
Araujo-Mariz C; Militão de Albuquerque MFP; Lopes EP; Ximenes RAA; Lacerda HR; Miranda-Filho DB; Lustosa-Martins BB; Pastor AFP; Acioli-Santos B
Ann Hepatol; 2020; 19(2):153-160. PubMed ID: 31734174
[TBL] [Abstract][Full Text] [Related]
17. N-acetyltransferase 2, cytochrome P4502E1 and glutathione S-transferase genotypes in antitubercular treatment-induced hepatotoxicity in North Indians.
Rana SV; Sharma SK; Ola RP; Kamboj JK; Malik A; Morya RK; Sinha SK
J Clin Pharm Ther; 2014 Feb; 39(1):91-6. PubMed ID: 24188272
[TBL] [Abstract][Full Text] [Related]
18. NAT2 slow acetylator is associated with anti-tuberculosis drug-induced liver injury severity in indonesian population.
Yuliwulandari R; Prayuni K; Susilowati RW; M Sofro AS; Tokunaga K; Shin JG
Pharmacogenomics; 2019 Dec; 20(18):1303-1311. PubMed ID: 31699005
[No Abstract] [Full Text] [Related]
19. Relevance of
Cheng F; Qiu CC; Jiang XG; Wu T; Zhang Q; Chen X; Zheng SL; Liu SD; Ye XC; Shi JC
Pharmacogenomics; 2024 Jan; 25(1):21-28. PubMed ID: 38131213
[TBL] [Abstract][Full Text] [Related]
20. Determining the relation between N-acetyltransferase-2 acetylator phenotype and antituberculosis drug induced hepatitis by molecular biologic tests.
Bozok Cetintaş V; Erer OF; Kosova B; Ozdemir I; Topçuoğlu N; Aktoğu S; Eroğlu Z
Tuberk Toraks; 2008; 56(1):81-6. PubMed ID: 18330759
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
